Skip to content
lifestyle.side.cr
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Erasca, Inc.
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
April 27, 2026
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
April 27, 2026
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
March 5, 2026
←
Previous Page
1
2